Fig. 4

Oral administration of lomerizine rescues the FD phenotypes of FD-mice. (a) Schematic outlining the protocol by which FD-mice (Gla^−/−/TSP1^Tg) were treated with lomerizine (10 or 30 mg/kg/day for 6 months) before being subjected to assays like echocardiography, sweat tests, and thermal pain tests. Control FD-mice received oral DMSO. (b) Echocardiographic measurements of cardiac function in WT (n = 3) and FD-mice treated with DMSO (n = 4) or lomerizine at 10 or 30 mg/kg (n = 8 and 7 per group). The left ventricle mass/body weight, ejection fraction, fractional shortening, and cardiac output were measured. Lomerizine improved the cardiac function of FD-mice. Data are presented as means ± SEM; *p < 0.05, **p < 0.01, and ***p < 0.001 via a Student’s t-test. (c) Analysis of sweat secretion from WT and FD mice treated with or without lomerizine. Data are presented as means ± SEM (n = 4); *p < 0.05 and **p < 0.01 via a Student’s t-test. (d) Heat tolerance analysis of WT (n = 5) and FD mice treated with or without lomerizine (n = 5). Increased latency of paw withdrawal indicates hyposensitivity to thermal pain. Data are presented as means ± SEM; *p < 0.05 and **p < 0.01 via a Student’s t-test.